Baxter International BAX and Onconova Therapeutics, Inc. today
announced that they have entered into a European licensing agreement for
rigosertib, a novel targeted anti-cancer compound currently in a Phase III
study for the treatment of a group of rare hematologic malignancies called
Myelodysplastic Syndromes (MDS) and in a Phase II/III study for pancreatic
cancer.
Under the terms of the agreement, Baxter will obtain commercialization rights
in the European Union and other countries in Europe. Baxter will make an
upfront payment of $50 million to Onconova, which will be recorded as a
special pre-tax in-process research and development charge in the third
quarter of 2012. In addition, Onconova may receive up to $515 million in
pre-commercial development and regulatory milestones for the MDS and
pancreatic cancer indications, in addition to sales milestones and royalties.
Baxter has the option to participate in the development and commercialization
of rigosertib in additional indications. Baxter has an existing equity
investment with Onconova of $50 million.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in